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Case Report
Abstract
Malaria is endemic in Nigeria. With the emergence of chloroquine resistance various modes of treatment including 
parenteral quinine are employed with consequent untoward effects. This article reports two cases of severe ocular 
toxicity, including mimicry of intracranial space-occupying lesion, from treatment of malaria with various drugs including 
quinine. Medical practitioners are advised to exhaust other less toxic modes of therapy before using drugs with great 
potential for severe untoward effects such as quinine.
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Introduction
Malaria is an infectious illness caused by protozoa of the 
plasmodium species.[1] The infective agent (plasmodium) 
is innoculated into the blood stream through the bite of 
mosquito that is the vector of plasmodium.[1] Malaria, which 
is endemic in Nigeria, has protean symptoms including bitter 
taste, nausea, vomiting, high fever, and headache.
For a long time, chloroquine administration was the standard 
treatment.[1,2] However, in the past few decades chloroquine 
resistance has become widespread. This has led to the use 
of other modes of therapy including quinine, amodiaquine, 
artemisin, doxycycline, pyrimethamine‑sulfonamide, and 
combination of these.[1,2]
Treatment regimen involving quinine may be associated 
with ophthalmic, cardiac, and oto‑rhinolaryngological 
complications.[3] This article reports on two cases of serious 




A 20‑year‑old female undergraduate presented on 28 August 
2003 at the Ebony Eye Specialist Clinic Onitsha with a 
week history of double vision, eye ache, and nuchal ache. 
Four days earlier she had developed acute febrile illness for 
which a blood film examination was remarkable for malaria 
parasite. She was admitted and treated by a general medical 
practitioner with intravenous infusion of 5% dextrose 
solution, injections of analgin, diclofenac, promethazine, 
quinine sulfate, and vitamin B‑complex.
Examination showed a well nourished but anxious lady. 
The right visual acuity was 6/12 and the left was 6/60. 
The right eye had florid papilledema and peripapillary 
retinal hemorrhage. The left eye had relative afferent 
pupillary defect, convergent squint, complete absence of 
abduction, florid papilledema, and retinal hemorrhage. 
There was no demonstrable diplopia. The intraocular 
pressure in each eye was 12 mmHg. An initial impression 
of intracranial space‑occupying lesion was made. Visual 
fields and computerized tomography (CT scan) were 
ordered.
She was advised to stop all her previous medication and 
we commenced her on hydrocortisone eye drops; oral 
dexamethasone (0.5 mg, three times daily), paracetamol, 
and folic acid. Visual fields showed tunnel vision in the 
Ocular complications of malaria treatment
SNN Nwosu
Guinness Eye Center, Onitsha, Nigeria





96 Nigerian Journal of Clinical Practice •Jan-Mar 2012 • Vol 15 • Issue 1
Nwosu: Malaria treatment and the eye 
right eye and the left could not fixate the test target. CT 
scan was normal.
Three days later, the nuchal and eye aches had subsided; 
degree of papilledema clinically reduced and visual acuity 
had improved to 6/9 in the right eye and 6/36 in the 
left. Six weeks after presentation the visual acuity was 
6/6 in each eye; each eye had full extraocular muscle 
movements; the retinal; hemorrhages and papilledema 
had completely resolved and other systemic symptoms 
abated. A repeat perimetry showed normal visual fields 
in each eye.
Case 2
A 32‑year‑old female factory worker presented at the 
Guinness Eye Center Onitsha on 9 June 2009 with a 3 week 
history of visual obscuration following treatment for acute 
malaria. She was referred from the Medical Outpatients 
Department of the Nnamdi Azikiwe University Teaching 
Hospital Nnewi. The referral letter documented that she 
had been treated for laboratory proven chloroquine‑resistant 
malaria with injections of quinine sulfate, oral ciprofloxacin, 
and pyrimethamine‑sulfonamide (maloxine).
Examination showed a fully conscious but anxious woman. 
The right visual acuity was 6/12 and the left was 6/9. Each 
eye had florid papilledema, preretinal hemorrhage, and 
widespread cotton wool spots. In addition, the right eye 
had convergent squint, reduced abduction, and macula 
edema. The intraocular pressure in the right eye was 16 and 
14 mmHg in the left. A clinical impression of drug‑induced 
combined retinopathy and optic neuropathy was made. 
She was sent for visual fields test that showed marked 
constriction and paracentral scotoma in the right eye and 
peripheral depression in the left.
Treatment was with oral prednisolone (80 mg per day 
in divided doses), analgesics, and multivitamin and she 
was followed up weekly. Four weeks after presentation 
the right visual acuity had improved to 6/9 and the left 
to 6/6. The papilledema and macula edema had clinically 
reduced; the cotton wool spots had completely resolved. 
There was improved extraocular muscle movement 
though 15°  esotropia was  still  present. At  this  point  the 
steroid was tapered off for the next 4 weeks. A year after 
initial presentation the convergent squint had completely 
subsided and all the retinal and optic nerve features had 
fully resolved.
Discussion
Malaria is a disease every medical practitioner in our 
environment is bound to treat since it is endemic. However, 
the emergence of resistance to the hitherto standard 
treatment with chloroquine has led to the use of other modes 
of therapy.[1,2] Quinine is one of the earliest antimalarial 
drugs.[1] But due to its systemic toxicity and the availability 
of the relatively less toxic drugs it lost its pride of place as 
the first line drug for treating malaria.
However, with the emergence of resistance to the routine 
malarial drugs such as chloroquine and pyrimethamine‑
sulphonamide combinations, there is a surge toward 
the use of quinine as an initial therapeutic modality 
for malaria. Reports abound in the literature of the 
untoward effects of quinine (cinchonism) on the heart 
where it could cause death in overdose; the central 
nervous system toxicity manifests as stupor, delirium, 
coma and seizures; ear toxicities include tinnitus and 
deafness.[3‑5] Ocular toxicity from quinine includes visual 
impairment and permanent blindness. Other ophthalmic 
abnormalities include reduced central visual acuity, 
pupillary abnormalities(vermiform motion), constricted 
visual fields, and dyschromatopsia.[4]
It is to be emphasized that our patients had, in addition 
to quinine, taken other drugs including antibiotics 
(ciprofloxacin) and chemotherapeutic agents (promethazine, 
sulphonamides, and pyrimethamine). However, none of 
these drugs is known to cause the type of severe visual 
symptoms that our patients presented with. We had 
suspected space‑occupying lesion in our first patient, but 
the CT scan was unremarkable. The knowledge gained from 
managing our first patient made us to emphasize perimetry 
alone for our second patient. It is not certain that the 
medicines we gave to our patients had any specific effect in 
counteracting the effect of quinine. We recommend basic 
science research for an answer to this. While oral charcoal, 
laxatives, and plasmapheresis will lower serum quinine it 
is not clear that such measures in any way ameliorate the 
retinal toxicity which is speculated to be due to blockade 
of cholinergic transmission.[4]
Drug resistant malaria is a great challenge to the medical 
practitioner in an endemic area such as Nigeria. When 
confronted with life‑threatening malaria, he may be forced 
to apply drugs with severe side effects. Quinine may not be 
tolerated by some patients even when given in therapeutic 
doses, it could cause permanent blindness and even 
death with overdose.[5] Therefore, medical practitioners 
using this drug should regularly monitor the patients’ 
kidney function and target organ toxicity including ocular 
toxicity.
Finally given the poor therapeutic safety of quinine it is 
advised that less toxic modes of therapy be exhausted 
before the use of quinine. While patients also need be 
educated on the many side effects of quinine, the medical 
practitioner, including the ophthalmologist, should be aware 
that ocular manifestation of these untoward effects could 
mimic intracranial space‑occupying lesion.
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